GTHX G1 Therapeutics, Inc.

33.70-2.07 (-5.79%)
Close: August 23, 2019

34.480.78 (+2.32%)
Pre-market

Quote

Previous Close
$33.70
Day Range
$33.38-$36.34
52 Week Range
$13.87-$69.57
Volume
271,505
Avg Volume
363,491
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$1.26B
Enterprise Value (EV)
$972.91M
PE Ratio
-
EV/EBITDA
-10.92
Price/Sales
-
Price/Book
3.52
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$175.00K
EBITDA
-$89.11M
EPS, ttm
-$2.70
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/11/2019 (78 days)
Debt to Equity
-
Debt
$77.67M
Cash
$369.29M
Net Debt
-

Performance

Beta
2.20
200 Day Moving Avg
$24.30
50 Day Moving Avg
$28.46
52 Week Change
-41.96%
YTD Change
66.50%
1 Month Change
21.49%
3 Month Change
48.85%
6 Month Change
66.91%
1 Year Change
-41.96%
2 Year Change
50.33%
5 Year Change
50.33%

Share Count

Shares Outstanding
37.5M
Float
31.3M
Restricted Shares
6.2M
Restricted Shares, %
16.64%

G1 Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Mark A. Velleca

Website: http://www.g1therapeutics.com

Description: G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Employees: 84